Transgene Biotek

Transgene Biotek EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Transgene Biotek (526139.BO) as of Oct 30, 2026 is -2,052.64. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -44.66 — a change of 4,495.80% (lower).

EV/FCF

-2,052.64

YoY

4,495.80%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene Biotek is 2026 -2,052.64 . EV/FCF (Enterprise Value to Free Cash Flow) of Transgene Biotek was 2025 -44.66 . It decreases by 4,495.80% lower compared to the previous year.

The Transgene Biotek EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2019
-11.29 INR
Jan 1, 2020
148.32 INR
Jan 1, 2021
-1,412.98 INR
Jan 1, 2022
216.38 INR
Jan 1, 2023
-16,418.77 INR
Jan 1, 2024
4,668.15 INR
Jan 1, 2025
-44.66 INR
Jan 1, 2026
-2,052.64 INR
The Transgene Biotek EV/FCF history
YEAREV/FCFYoY
-2,052.64+4,495.80%
-44.66-100.96%
4,668.15-128.43%
-16,418.77-7,687.77%
216.38-115.31%
-1,412.98-1,052.65%
148.32-1,413.21%
-11.29-51.70%
-23.38-92.46%
-310.13-6,441.06%
4.89-44.01%
8.74+102.02%
4.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene Biotek is -2,052.64 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Transgene Biotek changed from -44.66 to -2,052.64, representing a 4,495.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Transgene Biotek with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Transgene Biotek

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Transgene Biotek